Therapy Areas: Infectious Diseases
Aarvik Therapeutics Publishes Validation of Novel Tetravalent Antibody Platform
19 August 2022 - - US-based Aarvik Therapeutics co-founder Sachdev Sidhu, Ph.D. and his colleagues recently published a study validating the novel tetravalent antibody platform that forms a core component of innovation at Aarvik, the company said.

This study by Miersch et al. uses modular design principles to combine neutralizing antibodies against two independent epitopes of the SARS-COV-2 spike protein into a single bi-paratopic, tetravalent antibody.

The tetravalent antibody behaves like conventional IgGs on yield, purity, stability, and solubility but demonstrates potency and breadth of coverage that far exceed conventional bivalent IgGs.

This tetravalent antibody platform offers enormous potential not just in infectious disease but also in oncology and other therapeutic areas.

The proprietary tetravalent antibody platform enables the efficient creation of antibodies in a high-throughput manner. Aarvik utilizes this platform to rapidly design and generate tetravalent antibodies against a variety of oncology targets.

These antibodies can elegantly combine multiple independent antibody paratopes to potentially improve the clinical activity of various therapeutic modalities, including antibody drug conjugates, which currently use conventional IgG antibodies.

Aarvik Therapeutics combines a unique, proprietary modular platform with multiple target mechanisms and therapeutic modalities to develop novel molecules with an improved therapeutic index for oncology and other diseases.
Login
Username:

Password: